Blog
RSS FeedPosted by Michael Wonder on 28 Jul 2020
CADTH publishes final recommendation for a new combination product for HIV infection
24 July 2020 - Cabenuva (cabotegravir and rilpivirine extended release injectable suspensions) is indicated as a complete regimen for the treatment ...
Posted by Michael Wonder on 27 Jul 2020
CADTH posts final recommendation for Aimovig
26 July 2020 - Final recommendation informed by input from Migraine Canada and Migraine Quebec. ...
Posted by Michael Wonder on 26 Jul 2020
'I need something to move forward,' says Edmonton mom waiting for approval for son's life saving treatment
24 July 2020 - The family of a little boy in need of a $3 million treatment says they have ...
Posted by Michael Wonder on 23 Jul 2020
CADTH publishes final recommendation for Mayzent
23 July 2020 - The recommendation relates to the use of siponomid for the treatment of patients with secondary progressive multiple ...
Posted by Michael Wonder on 22 Jul 2020
Pandemic creating potential for drug shortages that Canada isn't equipped to deal with
22 July 2020 - Canada needs to become self-reliant in developing and supplying its own critical drugs, vaccines. ...
Posted by Michael Wonder on 20 Jul 2020
HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price
20 July 2020 - CADTH recommends Vascepa be reimbursed for patients with established cardiovascular disease under certain conditions. ...
Posted by Michael Wonder on 20 Jul 2020
CADTH publishes final recommendation for Stelara
20 July 2020 - CADTH has completed its assessment of ustekinumab by intravenous injection for the treatment of adult patients ...
Posted by Michael Wonder on 18 Jul 2020
'Heartbreaking': Alberta families describe waiting for life-changing drug to be made available in Canada
17 July 2020 - More families are hoping a one-time treatment option for a rare condition will be made available ...
Posted by Michael Wonder on 14 Jul 2020
Dupixent (dupilumab) receives positive recommendation from INESSS for the treatment of moderate to severe atopic dermatitis in adolescents
14 July 2020 - The Institut national d'excellence en santé et en services sociaux (INESSS) recommends extending existing coverage in Quebec ...
Posted by Michael Wonder on 14 Jul 2020
PMPRB changes within scope of Patent Act, rules federal court in judicial review
13 July 2020 - The Federal Court has upheld reforms to the Patented Medicines Pricing Review Board that updated the ...
Posted by Michael Wonder on 06 Jul 2020
Canadians demand access to ‘miracle’ cystic fibrosis drug already approved in U.S. and U.K
6 July 2020 - Montreal’s Chelsea Gagnon may look like a healthy 31-year-old woman at first glance, but every single ...
Posted by Michael Wonder on 05 Jul 2020
Clock ticking on Edmonton family's hope for $2.8 million drug treatment for toddler son
3 July 2020 - Family hoping Alberta Health will pay for new drug that must be administered by mid-July. ...
Posted by Michael Wonder on 30 Jun 2020
Canada federal court dismisses drug makers' plea challenging drug price rules
30 June 2020 - The federal court of Canada on Monday dismissed a plea by drug makers challenging the Canadian ...
Posted by Michael Wonder on 29 Jun 2020
IMC responds to Federal Court decision regarding PMPRB regulatory changes
29 June 2020 - Innovative Medicines Canada released the following statement today in response to the Federal Court of Canada’s ...
Posted by Michael Wonder on 25 Jun 2020
Consultation on CADTH’s drug reimbursement review procedures
25 June 2020 - CADTH is inviting stakeholder feedback on a revised procedure for its drug reimbursement review processes (i.e., pan-Canadian ...